John is based in San Diego. His recent transaction experience, as a director/CEO, includes Benitec Biopharma (US IPO), Medistem (acquired by Intrexon), Arana (acquired by Cephalon) and Domantis (acquired by GSK). Prior to Scancell John was CEO of Polynoma, a Phase III cancer vaccine company, based in San Diego.
Richard was formerly in senior management at Astra where he ran international clinical trials on Astra’s gastrointestinal and cardiovascular products including omeprazole before becoming Director of international Product Marketing. Thereafter he co-founded Paradigm Therapeutics (acquired by Takeda) and was a Board Director of Enact Pharma (acquired by Protherics/BTG) before co-founding Scancell with Lindy Durrant.
Lindy is an internationally recognised immunologist in the field of tumour therapy, She has worked for over 20 years in translational research, developing products for clinical trials including monoclonal antibodies for diagnostic imaging and therapy and cancer vaccines. She has a personal Chair in Cancer Immunotherapy at the Department of Clinical Oncology at the University of Nottingham.
Dr Sally Adams was Head of Neurology & Virology at British Biotech and Development Director at Neures Limited before becoming an independent consultant providing drug development and management services within the biotechnology and pharmaceutical sectors, specialising in biological entities. She has worked on many complex projects over the past 25 years including anti-infective vaccines, cancer immunotherapies and an innovative stem cell treatment for visual dysfunction. Sally previously worked as a development consultant to Scancell, providing guidance on the development of SCIB1, before her appointment as Development Director in May 2014.
Matthew started his career as a clinical and research scientist before moving to venture capital in 1999. He originally joined Oxford Technology Management making seed investments into start-up and early stage technology companies, predominantly in healthcare. More recently, he co-founded Longwall Venture Partners, an early-stage technology investment company with £70m under management. Matthew has a DPhil in Biochemistry from the University of Oxford.
Kate is a Chartered Financial Analyst and holds a Masters in Business Administration. She was managing director and head of Morgan Stanley Investment Management’s Global Core Equity Team between 2002 and 2004. Prior to this she was an executive director and senior portfolio manager within the same team at Morgan Stanley. More recently Kate has acted as a consultant providing financial research to private equity and financial training firms and was appointed a director of Investec Structured Products Calculus VCT plc in February 2011.
Alan has a proven track record in the US life sciences industry and is currently President and CEO of DiaVacs, a San Diego based clinical stage biotechnology company. He has held senior positions at a number of life science companies including Celgene, Ambit Biosciences, Medistem, Novocell and Signal Therapeutics. Whilst CEO at Signal Therapeutics Alan oversaw multi-year alliances with leading pharmaceutical companies including Akzo Nobel, Roche Biosciences and Novartis and subsequently managed its $275 million acquisition by Celgene. He is also on the Board of Directors of NASDAQ listed companies Biomarin and Assembly Biosciences.
Wei Xue, Rachael Metheringham, Victoria Brentville, Katherine Cook, Peter Symonds, Ian Daniel and Lindy Durrant
L.G. Durrant, C.Ottensmeier, C. Mulatero, P.Lorigan, R.Plummer, R.Metheringham, V.Brentville, L.Machado, I.Daniels, D.Hannaman & P.M.Patel
Wei Xue, Victoria Brentville, Rachael Metheringham, Katherine Cook, Peter, Symonds, Ian Daniel, and Lindy Durrant
V.Brentville, W.Xue, P.Symonds, K.Cook, B.Gunn, R.Metheringham and L.G. Durrant
Katherine Cook, Ian Daniels, Victoria Brentville, Rachael Metheringham, Wei Xue, Peter Symonds, Tracy Pitt, Mohamed Gijon and Lindy Durrant
Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Katherine Cook, Wei Xue, and Lindy G. Durrant
P.M Patel, C Ottensmeier, C Mulatero, P Lorigan, R Plummer, M Cunnell, R Metheringham, V Brentville, L Machado, I Daniels, D Hannaman, L.G Durrant
Victoria A Brentville, Rachael L Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Wei Xue, Lindy G Durrant
High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
Victoria A. Brentville, Rachael L. Metheringham, Barbara Gun and Lindy G. Durrant
Using monoclonal antibodies to stimulate antitumour cellular immunity
Lindy Durrant, Victoria Pudney and Ian Spendlove
ASCO poster June 2014
P.M Patel, L.G Durrant, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, M. Cunnell, R. Metheringham, V. Brentville, L. Machado, I. Daniels and D. Hannaman
Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses
Lindy Durrant, Victoria Pudney, Ian Spendlove and Rachel Metheringham
DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8 T cells
Victoria A. Pudney, Rachael L. Metheringham, Barbara Gunn, Ian Spendlove, Judith M. Ramage and Lindy G. Durrant
Antibodies designed as effective cancer vaccines
R.L. Metheringham, V.A. Pudney, B. Gunn, M. Towey, I. Spendlove and L.G. Durrant
Fri, 12 May 2017 07:57:00
The money will support clinical work on its pipeline of cancer immunotherapies and in particular Modi-1, the first product from its Moditope platform.
Thu, 11 May 2017 12:00:00
CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.
Wed, 01 Feb 2017 09:53:00